What is the recommended evaluation and management for erectile dysfunction?

Recommended Evaluation and Management for Erectile Dysfunction

Start with oral PDE5 inhibitors (sildenafil, tadalafil, vardenafil, or avanafil) as first-line treatment for erectile dysfunction unless contraindicated, while simultaneously evaluating cardiovascular risk factors since ED is a strong independent marker for cardiovascular disease. 1

Initial Evaluation

Critical History Components

• Cardiovascular risk assessment: ED predicts future cardiac events as strongly as smoking or family history of MI 1
• Testosterone screening: Check total testosterone if <300 ng/dL with symptoms—testosterone deficiency is present 1
• Medication review: Identify drugs causing ED (avoid thiazides/beta-blockers; prefer nebivolol or ARBs if antihypertensives needed) 2
• Psychological factors: Depression, anxiety, relationship conflict—these require concurrent psychotherapy referral 1
• Comorbidities: Diabetes, hypertension, dyslipidemia, obesity, lower urinary tract symptoms 3

Essential Laboratory Tests

• Fasting glucose and lipid profile 3
• Total testosterone level (in select cases, particularly if symptoms suggest deficiency) 3
• PSA test when clinically indicated 3

Physical Examination Focus

• Cardiovascular status
• Genital examination for anatomical abnormalities
• Signs of hypogonadism

Treatment Algorithm

First-Line: PDE5 Inhibitors

All four FDA-approved agents (sildenafil, tadalafil, vardenafil, avanafil) have similar efficacy—choose based on patient preference for duration of action and dosing flexibility. 1

Critical prescribing instructions to prevent treatment failure:

• Sexual stimulation is mandatory for drug efficacy 1
• Avoid taking with large meals 1
• Multiple trials (not just one) are required to establish efficacy 1
• Titrate dose up or down to balance efficacy against adverse effects (headache, flushing, dyspepsia, nasal congestion) 1

Special populations with reduced response:

• Diabetics and post-prostatectomy patients have more severe baseline ED and respond less robustly 1
• Severe renal or liver disease: PDE5i generally not recommended 1

Testosterone Combination Therapy

If testosterone <300 ng/dL with symptoms: combine testosterone therapy with PDE5i—this is more effective than PDE5i alone. 1 Testosterone monotherapy does NOT treat ED effectively 1.

Second-Line Options (When PDE5i Fail or Are Contraindicated)

Intracavernosal injection (ICI) therapy with alprostadil:

• Requires in-office test dose and training before home use 1
• Success rates: 60-65% can complete intercourse 3
• Effective in men with hypertension, diabetes, spinal cord injury 3

Intraurethral (IU) alprostadil:

• Must perform in-office test first 1
• Success rates: 29.5-78.1% (variable) 1
• Alternative for patients/partners preferring to avoid needles 1

Vacuum erection devices (VED):

• Only use devices with vacuum limiter 1
• Caution in patients on anticoagulants or with bleeding disorders 1
• Minor adverse effects: petechiae, bruising, ejaculatory difficulty 1

Third-Line: Surgical Treatment

Multicomponent inflatable penile implants for men refractory to all pharmacological/mechanical treatments—associated with high satisfaction rates. 3

Penile revascularization has poor outcomes and is not routinely recommended 3.

Cardiovascular Risk Stratification Before Treatment

Before prescribing ED treatment, assess cardiovascular fitness for sexual activity (approximately 3-5 METs). 2

Low-Risk (Safe for Sexual Activity and ED Treatment):

• Controlled hypertension
• Mild stable angina
• Post-MI >8 weeks, asymptomatic
• Mild valvular disease
• NYHA class I heart failure

High-Risk (Defer Sexual Activity Until Stabilized):

• Unstable or refractory angina
• Uncontrolled hypertension
• Recent MI (<2 weeks)
• NYHA class III-IV heart failure
• High-risk arrhythmias
• Obstructive cardiomyopathy
• Moderate-severe aortic stenosis

Indeterminate-Risk (Requires Exercise Stress Test):

• Mild-moderate stable angina
• Post-MI 2-8 weeks without intervention
• NYHA class III heart failure
• History of stroke/TIA or peripheral arterial disease

If patient completes 4 minutes of Bruce protocol (5-6 METs) without symptoms, arrhythmias, or BP drop, sexual activity is safe. 2

Concurrent Lifestyle Modifications

• Weight loss and exercise improve erectile function 2, 4
• Cardiovascular risk reduction improves vascular health including sexual function 2
• Statins may improve erectile function (though data are mixed) 2

Common Pitfalls to Avoid

• Incorrect PDE5i use accounts for most treatment failures—emphasize need for sexual stimulation and multiple trials 1
• Failing to screen for cardiovascular disease—ED diagnosis is a critical opportunity for CVD risk assessment 1
• Prescribing testosterone alone for ED—it doesn't work as monotherapy 1
• Not addressing psychological factors—always consider psychotherapy referral as adjunct 1
• Using VED without vacuum limiter—increases risk of injury 1